Core Viewpoint - The report outlines the independent financial advisory opinion regarding the 2025 restricted stock incentive plan of Fujian Wancheng Biotechnology Group Co., Ltd, emphasizing the plan's compliance with relevant laws and regulations [1][2][12]. Group 1: Incentive Plan Overview - The 2025 restricted stock incentive plan involves the issuance of 1,754,500 shares at an adjusted price of 69.18 RMB per share, targeting 68 eligible participants [7][8][11]. - The plan's total stock issuance represents 0.9352% of the company's total share capital and 80% of the planned restricted stock [8]. - The vesting schedule for the restricted stocks includes four phases, with 25% vesting at the end of each 12-month period over a total of 60 months [9]. Group 2: Approval Process - The approval process for the incentive plan included multiple meetings of the board and supervisory committee, with the final shareholder meeting held on May 15, 2025, to approve the plan [6][7]. - The plan underwent a public disclosure period from April 30 to May 9, 2025, during which no objections were raised [6]. Group 3: Adjustments and Compliance - Adjustments to the plan were made due to two participants no longer meeting eligibility criteria, reducing the number of participants from 70 to 68 and the total stock from 2,218,125 shares to 2,193,125 shares [8][10]. - The independent financial advisor confirmed that the plan meets all necessary legal and regulatory requirements, ensuring that the conditions for stock issuance are satisfied [12].
万辰集团: 上海妙道企业管理咨询有限公司关于福建万辰生物科技集团股份有限公司2025年限制性股票激励计划首次授予相关事项之独立财务顾问报告